Clinical Trial Update: A Phase 1, Open-label Safety Study of NKA in Patients With Type 2 Diabetes [Phase 1]

View source ↗

Summary

A Phase 1 open-label safety study of NKA in patients with Type 2 diabetes mellitus and chronic kidney disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• NKA

Snippet

Sponsor: Tengion | Conditions: Chronic Kidney Disease | Phase 1 | Status: TERMINATED